Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation.

Manciu M, Hosseini S, Desidero TD, Allegrini G, Falcone A, Bocci G, Kirken RA, Francia G.

Future Sci OA. 2018 Nov 1;4(10):FSO346. doi: 10.4155/fsoa-2018-0020. eCollection 2018 Dec.

2.

Precision therapeutic targeting of human cancer cell motility.

Xu L, Gordon R, Farmer R, Pattanayak A, Binkowski A, Huang X, Avram M, Krishna S, Voll E, Pavese J, Chavez J, Bruce J, Mazar A, Nibbs A, Anderson W, Li L, Jovanovic B, Pruell S, Valsecchi M, Francia G, Betori R, Scheidt K, Bergan R.

Nat Commun. 2018 Jun 22;9(1):2454. doi: 10.1038/s41467-018-04465-5.

3.

Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.

Fricke IB, De Souza R, Costa Ayub L, Francia G, Kerbel R, Jaffray DA, Zheng J.

PLoS One. 2018 May 3;13(5):e0196892. doi: 10.1371/journal.pone.0196892. eCollection 2018.

4.

Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors.

Orlandi P, Di Desidero T, Salvia G, Muscatello B, Francia G, Bocci G.

Biochem Pharmacol. 2018 Jun;152:327-337. doi: 10.1016/j.bcp.2018.04.011. Epub 2018 Apr 13.

PMID:
29660315
5.

Chronic graft versus host disease is associated with erectile dysfunction in allogeneic hematopoietic stem cell transplant patients: a single-center experience.

Andreini A, Zampieri N, Costantini C, Malerba G, Bruno C, Salvagno G, Francia G, Gottardi M, Rimondini M, Ferrarini I, Lippi G, Ambrosetti A, Benedetti F, Tecchio C.

Leuk Lymphoma. 2018 Mar 21:1-4. doi: 10.1080/10428194.2018.1443338. [Epub ahead of print] No abstract available.

PMID:
29561209
6.

Runx2 overexpression compromises bone quality in acromegalic patients.

Valenti MT, Mottes M, Cheri S, Deiana M, Micheletti V, Cosaro E, Davì MV, Francia G, Dalle Carbonare L.

Endocr Relat Cancer. 2018 Mar;25(3):269-277. doi: 10.1530/ERC-17-0523. Epub 2018 Jan 2.

PMID:
29295822
7.

Bone histomorphometry in acromegaly patients with fragility vertebral fractures.

Dalle Carbonare L, Micheletti V, Cosaro E, Valenti MT, Mottes M, Francia G, Davì MV.

Pituitary. 2018 Feb;21(1):56-64. doi: 10.1007/s11102-017-0847-1.

PMID:
29214508
8.

Bromoethylindole (BEI-9) redirects NF-κB signaling induced by camptothecin and TNFα to promote cell death in colon cancer cells.

Chowdhury R, Gales D, Valenzuela P, Miller S, Yehualaeshet T, Manne U, Francia G, Samuel T.

Apoptosis. 2017 Dec;22(12):1553-1563. doi: 10.1007/s10495-017-1427-6.

9.

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Di Desidero T, Antonelli A, Orlandi P, Ferrari SM, Fioravanti A, Alì G, Fontanini G, Basolo F, Francia G, Bocci G.

Cancer Lett. 2017 Dec 28;411:35-43. doi: 10.1016/j.canlet.2017.09.032. Epub 2017 Sep 28.

PMID:
28964784
10.

Study of the correlation between sensing performance and surface morphology of inkjet-printed aqueous graphene-based chemiresistors for NO2 detection.

Villani F, Schiattarella C, Polichetti T, Capua RD, Loffredo F, Alfano B, Miglietta ML, Massera E, Verdoliva L, Francia GD.

Beilstein J Nanotechnol. 2017 May 9;8:1023-1031. doi: 10.3762/bjnano.8.103. eCollection 2017.

11.

CVD transfer-free graphene for sensing applications.

Schiattarella C, Vollebregt S, Polichetti T, Alfano B, Massera E, Miglietta ML, Di Francia G, Sarro PM.

Beilstein J Nanotechnol. 2017 May 8;8:1015-1022. doi: 10.3762/bjnano.8.102. eCollection 2017.

12.

Effects of graphene defects on gas sensing properties towards NO2 detection.

Ricciardella F, Vollebregt S, Polichetti T, Miscuglio M, Alfano B, Miglietta ML, Massera E, Di Francia G, Sarro PM.

Nanoscale. 2017 May 11;9(18):6085-6093. doi: 10.1039/c7nr01120b.

PMID:
28443936
13.

Chemical Sensors and Biosensors in Italy: A Review of the 2015 Literature.

Compagnone D, Francia GD, Natale CD, Neri G, Seeber R, Tajani A.

Sensors (Basel). 2017 Apr 14;17(4). pii: E868. doi: 10.3390/s17040868. Review.

14.

The Development of Sensor Applications in the Sectors of Energy and Environment in Italy, 1976-2015.

Di Francia G.

Sensors (Basel). 2017 Apr 7;17(4). pii: E793. doi: 10.3390/s17040793. Review.

15.

Electronic Noses for Composites Surface Contamination Detection in Aerospace Industry.

Vito S, Miglietta ML, Massera E, Fattoruso G, Formisano F, Polichetti T, Salvato M, Alfano B, Esposito E, Francia GD.

Sensors (Basel). 2017 Apr 2;17(4). pii: E754. doi: 10.3390/s17040754.

16.

Resistance to metronomic chemotherapy and ways to overcome it.

Riesco-Martinez M, Parra K, Saluja R, Francia G, Emmenegger U.

Cancer Lett. 2017 Aug 1;400:311-318. doi: 10.1016/j.canlet.2017.02.027. Epub 2017 Mar 1. Review.

17.

Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study.

Davi' MV, Cosaro E, Piacentini S, Reimondo G, Albiger N, Arnaldi G, Faggiano A, Mantovani G, Fazio N, Piovesan A, Arvat E, Grimaldi F, Canu L, Mannelli M, Ambrogio AG, Pecori Giraldi F, Martini C, Lania A, Albertelli M, Ferone D, Zatelli MC, Campana D, Colao A, Scaroni C, Terzolo M, De Marinis L, Cingarlini S, Micciolo R, Francia G.

Eur J Endocrinol. 2017 Apr;176(4):451-459. doi: 10.1530/EJE-16-0809.

PMID:
28183788
18.

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.

Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G.

Br J Cancer. 2017 Jan;116(3):324-334. doi: 10.1038/bjc.2016.429. Epub 2017 Jan 5.

19.

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G.

Invest New Drugs. 2016 Dec;34(6):760-770. Epub 2016 Aug 24.

PMID:
27557783
20.

Label-Free Raman Imaging to Monitor Breast Tumor Signatures.

Manciu FS, Ciubuc JD, Parra K, Manciu M, Bennet KE, Valenzuela P, Sundin EM, Durrer WG, Reza L, Francia G.

Technol Cancer Res Treat. 2017 Aug;16(4):461-469. doi: 10.1177/1533034616655953. Epub 2016 Jul 4.

21.

A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells.

Robles-Escajeda E, Das U, Ortega NM, Parra K, Francia G, Dimmock JR, Varela-Ramirez A, Aguilera RJ.

Cell Oncol (Dordr). 2016 Jun;39(3):265-77. doi: 10.1007/s13402-016-0272-x. Epub 2016 Feb 26.

22.

p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer.

Li Y, Francia G, Zhang JY.

Oncotarget. 2015 Oct 20;6(32):32656-68. doi: 10.18632/oncotarget.5328.

23.

Morphological study of upper airways and long-term follow-up of obstructive sleep apnea syndrome in acromegalic patients.

Castellani C, Francia G, Dalle Carbonare L, Ferrari M, Viva E, Cerini R, Zaccarella A, Trevisiol L, Davi' MV.

Endocrine. 2016 Feb;51(2):308-16. doi: 10.1007/s12020-015-0659-x. Epub 2015 Jun 21.

PMID:
26093846
24.

The diverse toxic effect of SiO₂ and TiO₂ nanoparticles toward the marine microalgae Dunaliella tertiolecta.

Manzo S, Buono S, Rametta G, Miglietta M, Schiavo S, Di Francia G.

Environ Sci Pollut Res Int. 2015 Oct;22(20):15941-51. doi: 10.1007/s11356-015-4790-2. Epub 2015 Jun 10.

PMID:
26054456
25.

Positive (68)Ga-DOTATOC-PET/CT after cortisol level control during ketoconazole treatment in a patient with liver metastases from a pancreatic neuroendocrine tumor and ectopic Cushing syndrome.

Davi' MV, Salgarello M, Francia G.

Endocrine. 2015 Jun;49(2):566-7. doi: 10.1007/s12020-014-0391-y. Epub 2014 Aug 29. No abstract available.

PMID:
25168486
26.

Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.

Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G.

Cancer. 2014 Dec 15;120(24):3923-31. doi: 10.1002/cncr.28953. Epub 2014 Aug 8.

27.

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.

Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S.

Breast. 2013 Aug;22 Suppl 2:S57-65. doi: 10.1016/j.breast.2013.07.011. Review.

PMID:
24074794
28.

Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.

Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1465-73. doi: 10.1210/jc.2013-1364. Epub 2013 Aug 22.

PMID:
23969186
29.

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.

Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G.

Br J Cancer. 2013 Aug 20;109(4):957-64. doi: 10.1038/bjc.2013.398. Epub 2013 Jul 16.

30.

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U.

Invest New Drugs. 2014 Feb;32(1):47-59. doi: 10.1007/s10637-013-9974-3. Epub 2013 Jun 2.

PMID:
23728939
31.

Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas.

Toaiari M, Davì MV, Dalle Carbonare L, Boninsegna L, Castellani C, Falconi M, Francia G.

J Endocrinol Invest. 2013 Oct;36(9):753-8. doi: 10.3275/8942. Epub 2013 Apr 18.

PMID:
23608735
32.

Embryotoxicity and spermiotoxicity of nanosized ZnO for Mediterranean sea urchin Paracentrotus lividus.

Manzo S, Miglietta ML, Rametta G, Buono S, Di Francia G.

J Hazard Mater. 2013 Jun 15;254-255:1-9. doi: 10.1016/j.jhazmat.2013.03.027. Epub 2013 Mar 21.

PMID:
23571067
33.

Toxic effects of ZnO nanoparticles towards marine algae Dunaliella tertiolecta.

Manzo S, Miglietta ML, Rametta G, Buono S, Di Francia G.

Sci Total Environ. 2013 Feb 15;445-446:371-6. doi: 10.1016/j.scitotenv.2012.12.051. Epub 2013 Jan 23.

PMID:
23361041
34.

Focused ultrasound delivers targeted immune cells to metastatic brain tumors.

Alkins R, Burgess A, Ganguly M, Francia G, Kerbel R, Wels WS, Hynynen K.

Cancer Res. 2013 Mar 15;73(6):1892-9. doi: 10.1158/0008-5472.CAN-12-2609. Epub 2013 Jan 9.

35.

Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.

Bocci G, Fioravanti A, Orlandi P, Di Desidero T, Natale G, Fanelli G, Viacava P, Naccarato AG, Francia G, Danesi R.

Neoplasia. 2012 Sep;14(9):833-45.

36.

Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.

Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS.

Cancer Res. 2012 Oct 1;72(19):4909-19. doi: 10.1158/0008-5472.CAN-12-2194. Epub 2012 Aug 3.

37.

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.

Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS.

Gut. 2013 Feb;62(2):259-71. doi: 10.1136/gutjnl-2011-301585. Epub 2012 Apr 28.

38.

Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer.

Dalle Carbonare L, Frigo A, Francia G, Davì MV, Donatelli L, Stranieri C, Brazzarola P, Zatelli MC, Menestrina F, Valenti MT.

J Clin Endocrinol Metab. 2012 Jul;97(7):E1249-56. doi: 10.1210/jc.2011-2624. Epub 2012 Apr 17.

PMID:
22511796
39.

Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.

Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, Uhlik M, Dantzig AH, Foster FS, Kerbel RS.

Mol Cancer Ther. 2012 Mar;11(3):680-9. doi: 10.1158/1535-7163.MCT-11-0659. Epub 2011 Dec 21.

40.

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A.

J Endocrinol Invest. 2012 Oct;35(9):817-23. doi: 10.3275/8102. Epub 2011 Nov 9.

PMID:
22080849
41.

Presentation and outcome of pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1 syndrome.

Davì MV, Boninsegna L, Dalle Carbonare L, Toaiari M, Capelli P, Scarpa A, Francia G, Falconi M.

Neuroendocrinology. 2011;94(1):58-65. doi: 10.1159/000326164. Epub 2011 Apr 5.

PMID:
21464564
42.

Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS.

Nat Rev Cancer. 2011 Feb;11(2):135-41. doi: 10.1038/nrc3001. Review.

43.

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS.

Neoplasia. 2011 Jan;13(1):40-8.

44.

Investigation of ZnO nanoparticles' ecotoxicological effects towards different soil organisms.

Manzo S, Rocco A, Carotenuto R, Picione Fde L, Miglietta ML, Rametta G, Di Francia G.

Environ Sci Pollut Res Int. 2011 Jun;18(5):756-63. doi: 10.1007/s11356-010-0421-0. Epub 2010 Nov 30.

PMID:
21116865
45.
46.

Raising the bar for cancer therapy models.

Francia G, Kerbel RS.

Nat Biotechnol. 2010 Jun;28(6):561-2. doi: 10.1038/nbt0610-561. No abstract available.

PMID:
20531333
47.

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.

Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, Cremonini N, Seregni E, Orlandi F, Ferolla P, Puxeddu E, Giorgino F, Colao A, Loli P, Bondi F, Cosci B, Bottici V, Cappai A, Pinna G, Persani L, Verga U, Boscaro M, Castagna MG, Cappelli C, Zatelli MC, Faggiano A, Francia G, Brandi ML, Falchetti A, Pinchera A, Elisei R; ItaMEN network.

Eur J Endocrinol. 2010 Aug;163(2):301-8. doi: 10.1530/EJE-10-0333. Epub 2010 Jun 1. Erratum in: Eur J Endocrinol. 2010 Dec;163(6):963. Uberta, Verga [corrected to Verga, Uberta].

PMID:
20516206
48.

Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer.

Emmenegger U, Francia G, Shaked Y, Kerbel RS.

Recent Results Cancer Res. 2010;180:165-83. doi: 10.1007/978-3-540-78281-0_10.

PMID:
20033383
49.

Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.

Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, Kerbel RS.

Clin Cancer Res. 2009 Oct 15;15(20):6358-66. doi: 10.1158/1078-0432.CCR-09-0931. Epub 2009 Oct 13.

50.

Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal.

Frigo A, Dardano A, Danese E, Davì MV, Moghetti P, Colato C, Francia G, Bernardi F, Traino C, Monzani F, Ferdeghini M.

J Clin Endocrinol Metab. 2009 Sep;94(9):3472-6. doi: 10.1210/jc.2008-2830. Epub 2009 Jun 9.

PMID:
19509107

Supplemental Content

Loading ...
Support Center